These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16717260)

  • 41. Pharma Dynamics: targeting safe, effective and affordable medication for South Africa and neighbouring countries.
    Cardiovasc J Afr; 2009; 20(1):85. PubMed ID: 19287824
    [No Abstract]   [Full Text] [Related]  

  • 42. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 43. Inadequately met needs.
    Nat Biotechnol; 2011 May; 29(5):371. PubMed ID: 21552219
    [No Abstract]   [Full Text] [Related]  

  • 44. Pfizer is fined £84m for "exploiting opportunity" to hike price of phenytoin.
    Hawkes N
    BMJ; 2016 Dec; 355():i6628. PubMed ID: 27932377
    [No Abstract]   [Full Text] [Related]  

  • 45. Screaming for relief.
    Cooper M
    Time; 1999 Nov; 154(21):38-42, 44. PubMed ID: 10622838
    [No Abstract]   [Full Text] [Related]  

  • 46. The Price of Crossing the Border for Medications.
    Fralick M; Avorn J; Kesselheim AS
    N Engl J Med; 2017 Jul; 377(4):311-313. PubMed ID: 28745989
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug's 5000% price rise puts spotlight on soaring US drug costs.
    McCarthy M
    BMJ; 2015 Sep; 351():h5114. PubMed ID: 26404904
    [No Abstract]   [Full Text] [Related]  

  • 48. [The patent is "engine" in drug development].
    Bergström R
    Lakartidningen; 2008 Mar 5-11; 105(10):752. PubMed ID: 18422246
    [No Abstract]   [Full Text] [Related]  

  • 49. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
    Sturm AC
    Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
    [No Abstract]   [Full Text] [Related]  

  • 50. [Return the compass--but to whom?].
    Onfelt C
    Tidsskr Nor Laegeforen; 2006 Feb; 126(5):636; author reply 636. PubMed ID: 16505885
    [No Abstract]   [Full Text] [Related]  

  • 51. Brand name drug companies appear to hold winning hand in GATT talks.
    Spurgeon D
    CMAJ; 1992 Apr; 146(8):1429-30, 1432-4. PubMed ID: 1555172
    [No Abstract]   [Full Text] [Related]  

  • 52. White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
    Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Patients, patents and profits].
    Roland PC
    Tidsskr Nor Laegeforen; 2008 Jan; 128(2):205. PubMed ID: 18202741
    [No Abstract]   [Full Text] [Related]  

  • 54. Handle with care.
    Macilwain C
    Nature; 2006 Apr; 440(7087):990-1. PubMed ID: 16625170
    [No Abstract]   [Full Text] [Related]  

  • 55. [What drug companies actually do].
    Tonby K
    Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of privatization of the drug distribution system on drug prices in Malaysia.
    Babar ZD; Izham MI
    Public Health; 2009 Aug; 123(8):523-33. PubMed ID: 19665741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generic drug prices rose 3.4% in '93.
    Hosp Mater Manage; 1994 Feb; 19(2):1, 10-1. PubMed ID: 10132104
    [No Abstract]   [Full Text] [Related]  

  • 58. Huge price variations in generic drugs.
    James JS
    AIDS Treat News; 2003 May; (391):7-8. PubMed ID: 12866499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generic drug prices said headed up.
    Hosp Mater Manage; 1998 May; 23(5):1, 15. PubMed ID: 10179472
    [No Abstract]   [Full Text] [Related]  

  • 60. Market watch: Sales of biologics to show robust growth through to 2013.
    Goodman M
    Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.